Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00075959
Status:
COMPLETED
Last Update Posted:
2013-01-04
First Post:
2004-01-12
Brief Title:
Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
CHANT Cerebral Hemorrhage And NXY Treatment A Double-Blind Randomized Placebo-Controlled Parallel Group Multicenter Phase IIb Study to Assess the Safety and Tolerability of Intravenous Infusion of NXY-059 in Adult Patients With Acute Intracerebral Hemorrhage ICH
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CHANT | None | None | None |
| 0012 | None | None | None |